MediLink has signed an additional exclusive licensing agreement with Roche

CAR-T Digest - August 2020

09 January 2026: MediLink has signed an additional exclusive licensing agreement with Roche

MediLink Therapeutics announced that it has entered into an additional exclusive licensing and collaboration agreement with Roche for the global development and commercialisation of YL201, an investigational antibody–drug conjugate targeting B7-H3 across multiple solid tumor indications
Under the agreement, Roche receives exclusive rights to develop, manufacture, and commercialise YL201 worldwide outside mainland China, Hong Kong, and Macau, while MediLink is set to receive up to US$570 million in upfront and near-term milestone payments, along with additional development, regulatory, and commercial milestones and tiered royalties on net sales
This deal builds on the successful collaboration initiated in January 2024 around MediLink’s YL211 c-Met ADC program, further deepening the strategic partnership as both companies seek to accelerate the global development of YL201
By combining MediLink’s innovation-driven ADC platform capabilities with Roche’s extensive expertise in global oncology clinical development and commercialisation, the collaboration aims to expedite regulatory approvals and broaden worldwide patient access to YL201
Company leaders highlighted the agreement as a transformative step for YL201, positioning the asset to address significant unmet needs across solid tumors and reinforcing MediLink’s strategy of partnering globally to bring next-generation ADC therapies to patients as efficiently as possible